Annexon Inc (ANNX)

Currency in USD
6.375
-0.125(-1.92%)
Real-time Data·
ANNX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.1306.580
52 wk Range
2.0307.180
Key Statistics
Prev. Close
6.5
Open
6.5
Day's Range
6.13-6.58
52 wk Range
2.03-7.18
Volume
2.77M
Average Volume (3m)
3.35M
1-Year Change
165.625%
Book Value / Share
1.27
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ANNX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
14.875
Upside
+133.33%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings upwards for the upcoming period

Annexon Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

9 Buy
1 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 14.875
(+133.33% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Needham
Buy25.00+290.26%11.00MaintainJul 15, 2026
Cantor Fitzgerald
Buy---MaintainJul 13, 2026
Goldman Sachs
Hold7.00+9.27%-New CoverageMay 12, 2026
Jefferies
Buy10.00+56.10%-MaintainMar 31, 2026
H.C. Wainwright
Buy14.00+118.55%-MaintainMar 20, 2026

Earnings

Latest Release
May 07, 2026
EPS / Forecast
-0.23 / -0.28
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ANNX Income Statement

Compare ANNX to Peers and Sector

Metrics to compare
ANNX
Peers
Sector
Relationship
P/E Ratio
−5.4x−9.0x−0.4x
PEG Ratio
2.41−0.150.00
Price/Book
5.2x6.0x2.6x
Price / LTM Sales
-8,849.6x3.1x
Upside (Analyst Target)
100.0%174.9%51.8%
Fair Value Upside
Unlock−20.3%7.5%Unlock

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
61.23M37.37%397.96M
Other Institutional Investors
136.39M62.63%886.55M
Public Companies & Retail Investors
0.000.00%0.00
Total
197.62M100.00%1.28B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
FMR LLC11.91%19,518,424126,870
Redmile Group, LLC8.88%14,548,89694,568

People Also Watch

22.45
BIOA
-1.10%
9.46
REPL
-2.27%
1.62
NMRA
-0.61%
27.95
ALMS
-2.99%
52.800
ELVN
-0.68%

FAQ

What Is the Annexon (ANNX) Stock Price Today?

The Annexon stock price today is 6.375 USD.

What Stock Exchange Does Annexon Trade On?

Annexon is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Annexon?

The stock symbol for Annexon is "ANNX."

What Is the Annexon Market Cap?

As of today, Annexon market cap is 1.030B USD.

What Is Annexon's Earnings Per Share (TTM)?

The Annexon EPS (TTM) is -1.190.

When Is the Next Annexon Earnings Date?

Annexon will release its next earnings report on Aug 17, 2026.

From a Technical Analysis Perspective, Is ANNX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Annexon Stock Split?

Annexon has split 0 times.

How Many Employees Does Annexon Have?

Annexon has 93 employees.

What is the current trading status of Annexon (ANNX)?

As of Jul 16, 2026, Annexon (ANNX) is trading at a price of 6.375 USD, with a previous close of 6.500 USD. The stock has fluctuated within a day range of 6.130 USD to 6.580 USD, while its 52-week range spans from 2.030 USD to 7.180 USD.

What Is Annexon (ANNX) Price Target According to Analysts?

The average 12-month price target for Annexon is 14.875 USD, with a high estimate of 27 USD and a low estimate of 7 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +133.33% Upside potential.

What Is the ANNX Premarket Price?

ANNX's last pre-market stock price is 6.540 USD. The pre-market share volume is 7,700.000, and the stock has decreased by 0.040, or 0.620%.

What Is the ANNX After Hours Price?

ANNX's last after hours stock price is 6.740 USD, the stock has decreased by 0.240, or 3.690%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.